Left Ventricular Assist Device–Related Infection: Treatment and Outcome
Open Access
- 15 April 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (8), 1108-1115
- https://doi.org/10.1086/428728
Abstract
Background. Left ventricular assist device (LVAD) implantation has become an effective treatment option for patients with severe heart failure awaiting transplantation. Significant infection rates have been reported among LVAD recipients. However, few reports have focused specifically on device infection, its treatment, and the impact of LVAD-related infection on clinical outcome. Methods. Forty-six LVAD-related infections were diagnosed in 38 (50%) of 76 patients who underwent LVAD implantation as a bridge to transplantation. Twenty-nine episodes of LVAD-related bloodstream infection (BSI) (including 5 that were cases of LVAD endocarditis) and 17 episodes of local LVAD infection were identified. Results. Diabetes mellitus appeared to increase the risk of BSI among patients with LVAD infection. LVAD-related infection delayed transplantation, as reflected by longer device-support times (a mean duration ± SEM of 182.8 ± 31.1 days, compared with 66.3 ± 8.8 days; P ⩽ .001). Continuous antimicrobial treatment before, during, and after transplantation was associated with fewer relapses than was a limited course of antibiotics (P < .001). A trend for longer hospital stays after receipt of a transplant and increased early mortality was observed in the cohort with LVAD-related infection, although long-term survival was similar to that associated with patients without LVAD-related infection. Posttransplantation invasive vancomycin-resistant Enterococcus faecium (VREF) infection was diagnosed in 6 patients with LVAD-related infection; 4 of these patients died. No VREF infections were identified in patients without LVAD-related infection. Conclusions. Our observations suggest that LVAD-related infection is common and may require antimicrobial therapy before, during, and after transplantation, but that it does not prevent successful transplantation. However, patients with LVAD-related infection appear to be at increased risk for invasive VREF infection, which may contribute to early mortality after transplantation.Keywords
This publication has 15 references indexed in Scilit:
- LVAD bloodstream infections: therapeutic rationale for transplantation after LVAD infectionThe Journal of Heart and Lung Transplantation, 2003
- Infection in ventricular assist devices: prevention and treatmentThe Annals of Thoracic Surgery, 2003
- Do left ventricular assist device (LVAD) bridge-to-transplantation outcomes predict the results of permanent LVAD implantation?The Annals of Thoracic Surgery, 2002
- Left Ventricular Assist Device Infections: Three Case Reports and a Review of the LiteratureASAIO Journal, 2002
- Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantationThe Journal of Thoracic and Cardiovascular Surgery, 2001
- Long-Term Use of a Left Ventricular Assist Device for End-Stage Heart FailureNew England Journal of Medicine, 2001
- Left Ventricular Assist Device Infection Is Associated With Increased Mortality but Is Not a Contraindication to TransplantationCirculation, 1997
- Infectious Complications in Left Ventricular Assist Device RecipientsClinical Infectious Diseases, 1997
- Implantable LVAD infections: Implications for permanent use of the deviceThe Annals of Thoracic Surgery, 1996
- Vancomycin-Resistant Enterococcus faecium Bacteremia: Risk Factors for InfectionClinical Infectious Diseases, 1995